Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00911508 · ClinicalTrials.gov registry record · NA
Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
A NA study, sponsored by Mayo Clinic.
- Completed
- Registry status
- NA
- Development phase
- 2,204
- Enrollment target
NCT00911508: Completed NA study, sponsored by Mayo Clinic.
NCT00911508 is a NA study that has completed, run by Mayo Clinic. The registered enrollment target is 2,204 participants, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (57% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00911508, a NA study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- NA
- Development phase
- 2,204 participants
- Enrollment target
Study Summary
The (Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial) CABANA Trial has the overall goal of establishing the appropriate roles for medical and ablative intervention for atrial fibrillation (AF). The CABANA Trial is designed to test the hypothesis that the treatment strategy of left atrial catheter ablation for the purpose of eliminating atrial fibrillation (AF) will be superior to current state-of-the-art therapy with either rate control or rhythm control drugs for decreasing the incidence of the composite endpoint of total mortality, disabling stroke, serious bleeding, or cardiac arrest in patients with untreated or incompletely treated AF.
Primary Outcome
All events for each component of the primary endpoint were reviewed and adjudicated in a blinded fashion by an independent clinical events committee using prospectively determined event definitions. Death was defined as all-cause mortality, disabling stroke (including intracranial bleeding) as an irreversible physical limitation defined by a Rankin Stroke Scale ≥2, and serious bleeding as bleeding accompanied by hemodynamic compromise that required surgical intervention or a transfusion of ≥3 un
Interventions
- DEVICE Left atrial ablation
- DRUG Rate or Rhythm Control Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,204 participants |
| Start Date | 2009-11-13 |
| Est. Completion | 2017-12-31 |
| Phase | NA |
What the finished NCT00911508 record still lists
NCT00911508 is an interventional study that assigns participants to a tested intervention. Its 2,204 participants enrollment target places it among the larger protocols in the corpus, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (57% higher).
The record links to 0 conditions, and to 2 interventions - of which Left atrial ablation is the first listed.
NCT00911508 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00911508 about?
NCT00911508 is a clinical study titled "Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial". The (Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial) CABANA Trial has the overall goal of establishing the appropriate roles for medical and ablative intervention for atrial fibrillation (AF). The CABANA Trial is designed to test the hypothesis that the treatment...
What is the current status of trial NCT00911508?
This trial is currently completed. It is a NA study. The enrollment target is 2,204 participants. The study started on 2009-11-13. Estimated completion is 2017-12-31.
What interventions are being tested in trial NCT00911508?
The interventions under investigation include: Left atrial ablation (DEVICE), Rate or Rhythm Control Therapy (DRUG).
Who is sponsoring clinical trial NCT00911508?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00911508's enrollment target sits among peer trials
2,204 48th of 2000 higher than 1,953 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05654207 · 2,200 participants · NA
WeCare: A System of Care for Black Youth
- NCT06144554 · 2,200 participants
Post Market Registry for the Omnipod 5 System in Children and Adults With Type 1 Diabetes
- NCT06526988 · 2,200 participants · NA
Implementation and Interaction of Clinician And Patient-facing Tools Aiming to Intensify Neurohormonal Medicines for Heart Failure
- NCT06682650 · 2,200 participants · NA
Implementation of a ColoRectal Cancer Screening Tool in US Primary Care Practices - Usual Quality Improvement (10 Clinics) vs Normalization Process Theory-Participatory Learning in Action (10 Clinics)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI